Anna Meteliuk1, Tetiana Prokhorova2, Sergii Filippovych2, Danielle C Ompad3, Nickolas Zaller4. 1. International Charitable Foundation 'Alliance for Public Health', 5 Dilova Str., Building 10A, Kyiv, 03150, Ukraine. Electronic address: Meteliuk@gmail.com. 2. International Charitable Foundation 'Alliance for Public Health', 5 Dilova Str., Building 10A, Kyiv, 03150, Ukraine. 3. Department of Epidemiology, School of Global Public Health, New York University, 726 Broadway, 7th, Floor, New York, NY 10003, USA; Center for Drug Use and HIV/HCV Research, New York University, 665 Broadway, 10th Floor, New York, NY 10003, USA. 4. College of Public Health, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little, Rock, AR, 72205, USA.
Abstract
INTRODUCTION: Opioid agonist treatment (OAT) is an effective means to prevent HIV transmission. Ukraine started integrating HIV services into OAT sites to improve people who inject drugs' (PWID) access to treatment. METHODS: Data from the national registry of OAT patients (n = 9,983) were analyzed. These data are collected from all 179 OAT sites countrywide. For the cascade, HIV-positive OAT patients (n = 4,084) were stratified into two categories: OAT alone (received OAT at one site and antiretroviral therapy (ART) at different location, n = 1,789) and integrated care (received OAT and ART at one location, n = 2,295) for comparison. RESULTS: Most HIV-positive OAT patients in Ukraine are male (85.6 %) and the mean age is 40.3 years old. The mean length of injecting before OAT is 17.2 years and the mean length on OAT is 4.2 years. All HIV-positive OAT clients are aware of their HIV status. The proportion of HIV-positive clients receiving ART was higher at integrated care sites compared to OAT alone sites (84.2 vs. 73.1 %, p- = 0.012); distribution of viral suppression among those receiving ART across the strata were 79.4 and 59.2 % for 'integrated care sites' vs. 'OAT only sites' respectively (p < 0.001). CONCLUSIONS: This analysis clearly demonstrates much better progress towards the 90-90-90 goals among those OAT patients who receive integrated care services (both OAT and ART) at one site at each stage of the HIV care cascade as compared to receiving OAT and ART at different sites. There is an urgent need to further expand the integration of OAT and HIV services in Ukraine.
INTRODUCTION: Opioid agonist treatment (OAT) is an effective means to prevent HIV transmission. Ukraine started integrating HIV services into OAT sites to improve people who inject drugs' (PWID) access to treatment. METHODS: Data from the national registry of OAT patients (n = 9,983) were analyzed. These data are collected from all 179 OAT sites countrywide. For the cascade, HIV-positive OAT patients (n = 4,084) were stratified into two categories: OAT alone (received OAT at one site and antiretroviral therapy (ART) at different location, n = 1,789) and integrated care (received OAT and ART at one location, n = 2,295) for comparison. RESULTS: Most HIV-positive OAT patients in Ukraine are male (85.6 %) and the mean age is 40.3 years old. The mean length of injecting before OAT is 17.2 years and the mean length on OAT is 4.2 years. All HIV-positive OAT clients are aware of their HIV status. The proportion of HIV-positive clients receiving ART was higher at integrated care sites compared to OAT alone sites (84.2 vs. 73.1 %, p- = 0.012); distribution of viral suppression among those receiving ART across the strata were 79.4 and 59.2 % for 'integrated care sites' vs. 'OAT only sites' respectively (p < 0.001). CONCLUSIONS: This analysis clearly demonstrates much better progress towards the 90-90-90 goals among those OAT patients who receive integrated care services (both OAT and ART) at one site at each stage of the HIV care cascade as compared to receiving OAT and ART at different sites. There is an urgent need to further expand the integration of OAT and HIV services in Ukraine.
Authors: Kimberly Johnson; Irina Pinchuk; Marie Isabel E Melgar; Martin Osayande Agwogie; Fernando Salazar Silva Journal: Ann Med Date: 2022-12 Impact factor: 5.348
Authors: Tetiana Kiriazova; Vivian F Go; Rebecca B Hershow; Erica L Hamilton; Riza Sarasvita; Quynh Bui; Kathryn E Lancaster; Kostyantyn Dumchev; Irving F Hoffman; William C Miller; Carl A Latkin Journal: Harm Reduct J Date: 2020-10-01